Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 20:06 | 2026-03-05 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | GEMAYEL GEORGES | Director | OPT+S | $53.38 | 18,787 | $1,002,811 | 27,277 |
| 2026-03-09 20:34 | 2026-03-06 | LYEL | Lyell Immunopharma, Inc. | ARCH Venture Fund XIII, L.P. | 10% owner | BUY | $25.61 | 488,090 | $12,499,985 | 1,426,528 |
| 2026-03-09 20:36 | 2026-03-06 | UTHR | UNITED THERAPEUTICS Corp | Olian Judy D. | Director | SELL | $510.00 | 200 | $102,000 | 4,645 |
| 2026-03-09 20:36 | 2026-03-05 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $484.55 | 9,500 | $4,603,233 | 130 |
| 2026-03-09 21:20 | 2026-03-05 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | SELL | $63.38 | 3,989 | $252,823 | 2,737 |
| 2026-03-10 00:18 | 2026-03-05 | NAMS | NewAmsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Director, Officer | OPT+S | $30.30 | 300,000 | $9,090,870 | 69,302 |
| 2026-03-09 23:00 | 2026-03-05 | ARWR | Arrowhead Pharmaceuticals Inc. | Hamilton James C | Officer | SELL | $64.19 | 10,000 | $641,900 | 236,958 |
| 2026-03-09 22:12 | 2025-03-04 | BHVN | Biohaven Ltd. | CHILDS JOHN W | Director | BUY | $30.43 | 28,400 | $864,115 | 2,323,971 |
| 2026-03-09 21:20 | 2026-03-05 | PTCT | PTC THERAPEUTICS, INC. | Golden Lee Scott | Officer | SELL | $63.38 | 10,000 | $633,800 | 79,944 |
| 2026-03-09 21:20 | 2026-03-05 | PTCT | PTC THERAPEUTICS, INC. | Okey Stephanie | Director | SELL | $63.38 | 6,333 | $401,386 | 8,000 |
| 2026-03-09 21:15 | 2026-03-09 | JAZZ | Jazz Pharmaceuticals plc | Carr Patricia | Officer | SELL | $182.94 | 1,287 | $235,444 | 6,512 |
| 2026-03-09 20:14 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Hughes Eric A | Officer | OPT+S | $31.67 | 9,533 | $301,895 | 107,711 |
| 2026-03-09 20:16 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | Officer | OPT+S | $31.67 | 7,924 | $250,940 | 84,905 |
| 2026-03-09 20:18 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Francis Richard D | Officer | OPT+S | $31.67 | 20,025 | $634,160 | 1,170,639 |
| 2026-03-09 20:01 | 2026-03-05 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer | SELL | $15.00 | 20,251 | $303,765 | 112,622 |
| 2026-03-09 11:05 | 2026-03-06 | ALT | Altimmune, Inc. | WEAVER GREGORY L | Officer | BUY | $3.54 | 5,000 | $17,700 | 28,078 |
| 2026-03-09 11:00 | 2026-03-06 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Director, Officer | BUY | $3.54 | 20,000 | $70,790 | 32,500 |
| 2026-03-07 00:03 | 2026-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Savage Brian | Officer | OPT+S | $32.46 | 2,675 | $86,843 | 8,461 |
| 2026-03-07 00:05 | 2026-03-04 | VRTX | VERTEX PHARMACEUTICALS INC / MA | McKechnie Duncan | Officer | SELL | $475.30 | 2,437 | $1,158,306 | 15,122 |
| 2026-03-07 00:05 | 2026-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Fox Christine | Officer | OPT+S | $32.46 | 9,098 | $295,362 | 75,010 |
| 2026-03-07 00:17 | 2026-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | Officer | OPT+S | $32.66 | 91,345 | $2,983,520 | 85,755 |
| 2026-03-07 00:30 | 2026-03-04 | QURE | uniQure N.V. | KLEMT CHRISTIAN | Officer | SELL | $9.06 | 12,000 | $108,720 | 226,581 |
| 2026-03-07 00:08 | 2026-03-05 | DYN | Dyne Therapeutics, Inc. | Cox John | Director, Officer | SELL | $14.90 | 2,732 | $40,707 | 374,145 |
| 2026-03-07 00:30 | 2026-03-04 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $35.99 | 8,233 | $296,346 | 2,231 |
| 2026-03-07 03:18 | 2026-03-06 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | Officer | SELL | $430.87 | 1,982 | $853,992 | 12,490 |
| 2026-03-07 03:27 | 2026-03-04 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer | OPT+S | $18.74 | 8,234 | $154,325 | 339,392 |
| 2026-03-07 02:49 | 2026-03-06 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Sibold William John | Director, Officer | SELL | $431.94 | 1,663 | $718,316 | 161,829 |
| 2026-03-07 02:49 | 2026-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Espinoza Octavio | Officer | OPT+S | $205.83 | 13,423 | $2,762,823 | 21,662 |
| 2026-03-07 02:51 | 2026-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer | OPT+S | $206.35 | 5,000 | $1,031,771 | 36,869 |
| 2026-03-07 02:56 | 2026-03-05 | SION | Sionna Therapeutics, Inc. | Fitzpatrick Jennifer | Officer | OPT+S | $33.86 | 10,250 | $347,019 | 0 |
| 2026-03-07 02:34 | 2026-03-06 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Kelley Shannon T | Officer | SELL | $431.94 | 360 | $155,498 | 12,138 |
| 2026-03-07 02:15 | 2026-03-06 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Huntsman Carole | Officer | SELL | $431.94 | 419 | $180,983 | 12,692 |
| 2026-03-07 02:07 | 2026-03-06 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca | Director | SELL | $431.94 | 491 | $212,083 | 452,213 |
| 2026-03-07 01:26 | 2026-03-04 | SDGR | Schrodinger, Inc. | Abel Robert Lorne | Officer | SELL | $12.81 | 1,300 | $16,653 | 55,897 |
| 2026-03-07 01:26 | 2026-03-05 | SDGR | Schrodinger, Inc. | Lorton Kenneth Patrick | Officer | SELL | $12.90 | 1,222 | $15,761 | 89,241 |
| 2026-03-07 01:27 | 2026-03-05 | SDGR | Schrodinger, Inc. | Akinsanya Karen | Officer | SELL | $12.90 | 1,366 | $17,625 | 69,956 |
| 2026-03-07 01:28 | 2026-03-05 | SDGR | Schrodinger, Inc. | Farid Ramy | Director, Officer | SELL | $12.91 | 3,661 | $47,249 | 330,824 |
| 2026-03-07 01:28 | 2026-03-05 | SDGR | Schrodinger, Inc. | Tran Yvonne | Officer | SELL | $12.90 | 1,094 | $14,107 | 52,683 |
| 2026-03-07 01:29 | 2026-03-05 | SDGR | Schrodinger, Inc. | Jain Rachit | Officer | SELL | $12.90 | 1,631 | $21,033 | 52,596 |
| 2026-03-07 01:29 | 2026-03-05 | SDGR | Schrodinger, Inc. | Herman Jenny | Officer | SELL | $12.84 | 1,383 | $17,764 | 34,804 |
| 2026-03-07 01:01 | 2026-03-05 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | Director, Officer, 10% owner | BUY | $3.90 | 10,000 | $39,000 | 402,702 |
| 2026-03-07 01:05 | 2026-03-04 | ABBV | AbbVie Inc. | Purdue David Ryan | Officer | SELL | $233.56 | 5,230 | $1,221,519 | 2,654 |
| 2026-03-07 01:07 | 2026-03-04 | QURE | uniQure N.V. | Kapusta Matthew C | Director, Officer | SELL | $9.06 | 14,581 | $132,104 | 660,658 |
| 2026-03-07 00:51 | 2026-03-04 | RYTM | RHYTHM PHARMACEUTICALS, INC. | German Christopher Paul | Officer | OPT+S | $89.56 | 5,614 | $502,790 | 160 |
| 2026-03-07 00:55 | 2026-03-04 | GENB | Generate Biomedicines, Inc. | Nally Michael | Director, Officer | BUY | $12.00 | 20,000 | $240,000 | 572,707 |
| 2026-03-07 00:57 | 2026-03-04 | BBIO | BridgeBio Pharma, Inc. | Ellis Andrea | Director | OPT+S | $64.87 | 64,921 | $4,211,302 | 18,589 |
| 2026-03-07 00:59 | 2026-03-04 | QURE | uniQure N.V. | Abi-Saab Walid | Officer | SELL | $9.06 | 808 | $7,320 | 189,669 |
| 2026-03-07 00:35 | 2026-03-04 | QURE | uniQure N.V. | Potts Jeannette | Officer | SELL | $9.06 | 3,412 | $30,913 | 138,483 |
| 2026-03-07 00:36 | 2026-03-04 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | Officer | SELL | $12.25 | 7,988 | $97,892 | 137,987 |
| 2026-03-07 00:19 | 2026-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Francis Richard D | Officer | OPT+S | $32.46 | 23,393 | $759,442 | 1,148,212 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.